IN8bio Reports FY Loss and Launches $40.2M Private Placement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy INAB?
Source: seekingalpha
- Earnings Miss: IN8bio's FY GAAP EPS of -$4.44 falls short by $1.22, indicating significant challenges in profitability that could undermine investor confidence and negatively impact stock performance.
- Private Placement Announcement: The company has initiated a private placement of up to $40.2 million at-the-market, aimed at bolstering liquidity to support future R&D and operations, reflecting the urgency for funding amid current financial pressures.
- Quant Rating Insights: Seeking Alpha's Quant Rating on IN8bio suggests a cautious market outlook regarding its future performance, which may influence investor decisions and demand for its stock.
- Historical Financial Trends: Historical earnings data for IN8bio reveals a persistent trend of losses, prompting investors to closely monitor the company's potential for long-term profitability improvement to assess future investment risks and returns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INAB
Wall Street analysts forecast INAB stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.370
Low
36.00
Averages
92.00
High
180.00
Current: 1.370
Low
36.00
Averages
92.00
High
180.00
No data
About INAB
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IN8bio Reports FY Loss and Launches $40.2M Private Placement
- Earnings Miss: IN8bio's FY GAAP EPS of -$4.44 falls short by $1.22, indicating significant challenges in profitability that could undermine investor confidence and negatively impact stock performance.
- Private Placement Announcement: The company has initiated a private placement of up to $40.2 million at-the-market, aimed at bolstering liquidity to support future R&D and operations, reflecting the urgency for funding amid current financial pressures.
- Quant Rating Insights: Seeking Alpha's Quant Rating on IN8bio suggests a cautious market outlook regarding its future performance, which may influence investor decisions and demand for its stock.
- Historical Financial Trends: Historical earnings data for IN8bio reveals a persistent trend of losses, prompting investors to closely monitor the company's potential for long-term profitability improvement to assess future investment risks and returns.
See More
IN8bio Appoints New President and COO
- Executive Appointment: IN8bio has promoted Kate Rochlin to president and chief operating officer, effective immediately, recognizing her leadership since serving as COO since December 2021, which reflects the company's confidence in her capabilities.
- Funding Initiative: IN8bio plans to raise up to $40.2 million through an at-the-market private placement, aimed at strengthening its capital structure and providing financial support for future R&D and operations, thereby driving growth in the biopharmaceutical sector.
- Historical Performance Review: Historical financial data for IN8bio indicates robust revenue growth over the past fiscal year, showcasing the company's competitiveness and the sustained demand in the biopharmaceutical market.
- Quant Rating Insight: Seeking Alpha's Quant Rating on IN8bio reveals a positive market outlook for its future performance, potentially attracting more investor interest and enhancing the company's stock price performance.
See More
IN8bio Appoints Kate Rochlin as President and COO
- Executive Appointment: IN8bio has announced the immediate promotion of Dr. Kate Rochlin to President and Chief Operating Officer, having previously served as COO since December 2021, overseeing company operations and advancing clinical and preclinical pipelines, marking a strategic focus on growth.
- Leadership Enhancement: Dr. Rochlin has been instrumental in advancing IN8bio's clinical programs and T cell engager platform, with her leadership aligning teams across operations, manufacturing, clinical, and research, ensuring critical milestones are met on schedule, thereby enhancing the company's execution capabilities.
- Clinical Progress: Under her leadership, IN8bio's INB-619 project has made significant strides, with preclinical data showing that it achieved complete B cell depletion comparable to approved T cell engagers with minimal adverse effects, highlighting the company's competitive edge in the field of autoimmune diseases.
- Manufacturing Capability Expansion: Dr. Rochlin has also played a key role in developing and expanding IN8bio's clinical manufacturing program, leading analytical, quality, regulatory, and GMP manufacturing teams across multiple Phase 1 and 2 clinical programs in glioblastoma and hematological cancers, ensuring the company's sustained growth in these areas.
See More
IN8bio Unveils Private Placement Funding Initiative
Securities Purchase Agreement: IN8bio, Inc. has finalized a securities purchase agreement to raise approximately $40.2 million through a private placement involving new and existing institutional investors, as well as company directors and officers.
Funding Allocation: The funds from the initial closing, estimated at $20.1 million, will support operations until mid-2027 and facilitate IND-enabling studies for INB-619, along with regulatory efforts for glioblastoma programs INB-200 and INB-400.
Current Stock Performance: INAB's stock is currently trading at $1.36, reflecting a decrease of $0.02 or 1.45 percent on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
See More
IN8bio Secures $40.2 Million Financing to Advance INB-619
- Financing Amount: IN8bio has secured up to $40.2 million through a securities purchase agreement with institutional investors, with an initial $20.1 million aimed at advancing the IND application for INB-619, ensuring operational funding through the first half of 2027.
- Investor Participation: The financing is led by Coastlands Capital and includes participation from both new and existing investors such as Stonepine Capital Management and 683 Capital Partners, reflecting strong market confidence in IN8bio's innovative therapies.
- Equity Structure: The initial tranche involves the sale of 5,127,029 shares at $1.38 per share, along with pre-funded warrants, enhancing the company's capital flexibility and competitive positioning in the biopharmaceutical market.
- Clinical Research Plans: IN8bio intends to use the proceeds to fund IND enabling studies for INB-619, with expectations to engage with the FDA in 2026 and submit pivotal animal model data in 2027, thereby advancing the product's path to market.
See More
IN8bio Secures $20.1 Million Financing to Advance INB-619
- Financing Agreement: IN8bio has entered into a securities purchase agreement with institutional investors for an initial $20.1 million, expected to extend its cash runway into the first half of 2027, ensuring operational stability during clinical development.
- Follow-on Financing Potential: The agreement includes an additional $20.1 million in milestone-driven financing, which will enhance the company's research capabilities in oncology and autoimmune diseases if preclinical data for INB-619 meets specified criteria.
- Equity Structure Optimization: The financing will issue 5,127,029 shares of common stock at $1.38 per share, along with pre-funded warrants for 9,452,677 shares, enhancing investor engagement and the company's capital flexibility.
- FDA Interaction Plan: IN8bio plans to engage with the FDA in 2026 for initial discussions, with an IND submission anticipated in 2027, aimed at accelerating the clinical development of INB-619 and improving market competitiveness.
See More
IN8bio Reports FY Loss and Launches $40.2M Private Placement
- Earnings Miss: IN8bio's FY GAAP EPS of -$4.44 falls short by $1.22, indicating significant challenges in profitability that could undermine investor confidence and negatively impact stock performance.
- Private Placement Announcement: The company has initiated a private placement of up to $40.2 million at-the-market, aimed at bolstering liquidity to support future R&D and operations, reflecting the urgency for funding amid current financial pressures.
- Quant Rating Insights: Seeking Alpha's Quant Rating on IN8bio suggests a cautious market outlook regarding its future performance, which may influence investor decisions and demand for its stock.
- Historical Financial Trends: Historical earnings data for IN8bio reveals a persistent trend of losses, prompting investors to closely monitor the company's potential for long-term profitability improvement to assess future investment risks and returns.
See More
IN8bio Appoints New President and COO
- Executive Appointment: IN8bio has promoted Kate Rochlin to president and chief operating officer, effective immediately, recognizing her leadership since serving as COO since December 2021, which reflects the company's confidence in her capabilities.
- Funding Initiative: IN8bio plans to raise up to $40.2 million through an at-the-market private placement, aimed at strengthening its capital structure and providing financial support for future R&D and operations, thereby driving growth in the biopharmaceutical sector.
- Historical Performance Review: Historical financial data for IN8bio indicates robust revenue growth over the past fiscal year, showcasing the company's competitiveness and the sustained demand in the biopharmaceutical market.
- Quant Rating Insight: Seeking Alpha's Quant Rating on IN8bio reveals a positive market outlook for its future performance, potentially attracting more investor interest and enhancing the company's stock price performance.
See More
IN8bio Appoints Kate Rochlin as President and COO
- Executive Appointment: IN8bio has announced the immediate promotion of Dr. Kate Rochlin to President and Chief Operating Officer, having previously served as COO since December 2021, overseeing company operations and advancing clinical and preclinical pipelines, marking a strategic focus on growth.
- Leadership Enhancement: Dr. Rochlin has been instrumental in advancing IN8bio's clinical programs and T cell engager platform, with her leadership aligning teams across operations, manufacturing, clinical, and research, ensuring critical milestones are met on schedule, thereby enhancing the company's execution capabilities.
- Clinical Progress: Under her leadership, IN8bio's INB-619 project has made significant strides, with preclinical data showing that it achieved complete B cell depletion comparable to approved T cell engagers with minimal adverse effects, highlighting the company's competitive edge in the field of autoimmune diseases.
- Manufacturing Capability Expansion: Dr. Rochlin has also played a key role in developing and expanding IN8bio's clinical manufacturing program, leading analytical, quality, regulatory, and GMP manufacturing teams across multiple Phase 1 and 2 clinical programs in glioblastoma and hematological cancers, ensuring the company's sustained growth in these areas.
See More
IN8bio Unveils Private Placement Funding Initiative
Securities Purchase Agreement: IN8bio, Inc. has finalized a securities purchase agreement to raise approximately $40.2 million through a private placement involving new and existing institutional investors, as well as company directors and officers.
Funding Allocation: The funds from the initial closing, estimated at $20.1 million, will support operations until mid-2027 and facilitate IND-enabling studies for INB-619, along with regulatory efforts for glioblastoma programs INB-200 and INB-400.
Current Stock Performance: INAB's stock is currently trading at $1.36, reflecting a decrease of $0.02 or 1.45 percent on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
See More
IN8bio Secures $40.2 Million Financing to Advance INB-619
- Financing Amount: IN8bio has secured up to $40.2 million through a securities purchase agreement with institutional investors, with an initial $20.1 million aimed at advancing the IND application for INB-619, ensuring operational funding through the first half of 2027.
- Investor Participation: The financing is led by Coastlands Capital and includes participation from both new and existing investors such as Stonepine Capital Management and 683 Capital Partners, reflecting strong market confidence in IN8bio's innovative therapies.
- Equity Structure: The initial tranche involves the sale of 5,127,029 shares at $1.38 per share, along with pre-funded warrants, enhancing the company's capital flexibility and competitive positioning in the biopharmaceutical market.
- Clinical Research Plans: IN8bio intends to use the proceeds to fund IND enabling studies for INB-619, with expectations to engage with the FDA in 2026 and submit pivotal animal model data in 2027, thereby advancing the product's path to market.
See More
IN8bio Secures $20.1 Million Financing to Advance INB-619
- Financing Agreement: IN8bio has entered into a securities purchase agreement with institutional investors for an initial $20.1 million, expected to extend its cash runway into the first half of 2027, ensuring operational stability during clinical development.
- Follow-on Financing Potential: The agreement includes an additional $20.1 million in milestone-driven financing, which will enhance the company's research capabilities in oncology and autoimmune diseases if preclinical data for INB-619 meets specified criteria.
- Equity Structure Optimization: The financing will issue 5,127,029 shares of common stock at $1.38 per share, along with pre-funded warrants for 9,452,677 shares, enhancing investor engagement and the company's capital flexibility.
- FDA Interaction Plan: IN8bio plans to engage with the FDA in 2026 for initial discussions, with an IND submission anticipated in 2027, aimed at accelerating the clinical development of INB-619 and improving market competitiveness.
See More
